2
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2603 |
Spebrutinib
CC-292,LMK-435,AVL-292 |
Src; BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
Spebrutinib (LMK-435) 是一种共价的、高效的、选择性的、具有口服活性的Btk 抑制剂 (IC50:0.5 nM)。 | |||
T14357 |
Spebrutinib besylate
CC-292 (besylate),AVL-292 (benzenesulfonate) |
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s). |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-02271 |
BTK Protein, Human, Recombinant (His)
BPK,AGMX1,ATK,B-cell progenitor kinase,Tyrosine... |
Human | Baculovirus Insect Cells |
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in... |